Results 261 to 270 of about 3,067,072 (318)

JAK Inhibitors and Risk of Cancer in IBD Patients. [PDF]

Cancers (Basel)
Bernardi F, Faggiani I, Parigi TL, Zilli A, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S, D'Amico F.   +8 more
europepmc   +1 more source

Correction to “Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors”

Molecular Oncology, EarlyView.
wiley   +1 more source

EXPRESSION OF CONCERN: DIMP53‐1: A Novel Small‐Molecule Dual Inhibitor of p53–MDM2/X Interactions with Multifunctional p53‐Dependent Anticancer Properties

Molecular Oncology, EarlyView.
wiley   +1 more source

EXPRESSION OF CONCERN: A Newly Identified 45‐kDa JAK2 Variant with an Altered Kinase Domain Structure Represents a Novel Mode of JAK2 Kinase Inhibitor Resistance

Molecular Oncology, EarlyView.
wiley   +1 more source

An Update on JAK Inhibitors

Current Medicinal Chemistry, 2019
Janus kinases (JAKs) are a family of non-receptor tyrosine kinases, composed by four members, JAK1, JAK2, JAK3 and TYK2. JAKs are involved in different inflammatory and autoimmune diseases, as well as in malignancies, through the activation of the JAK/STAT signalling pathway.
Musumeci, Francesca, Greco, Chiara, Giacchello, Ilaria, Fallacara, Anna Lucia, Ibrahim, Munjed M, Grossi, Giancarlo, Brullo, Chiara, Schenone, Silvia   +7 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

JAK inhibitors for rheumatoid arthritis

Expert Opinion on Investigational Drugs, 2023
JAK (Janus kinase) is a type of non-receptor tyrosine kinase that includes JAK1, JAK2, JAK3, and Tyk2. Currently, there are five JAK inhibitors approved for treating rheumatoid arthritis. These inhibitors vary in their selectivity for different JAK isoforms.This review outlines the mode of actions and the results of Phase III trials of the JAK ...
Satoshi Kubo, Shingo Nakayamada, Yoshiya Tanaka   +2 more
openaire   +3 more sources

JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy

International Journal of Molecular Sciences
Rheumatoid arthritis (RA) is a highly prevalent autoimmune disorder. The pathogenesis of the disease is complex and involves various cellular populations, including fibroblast-like synoviocytes, macrophages, and T cells, among others.
Andrzej Pawlik, Estera Bakinowska, Aleksandra Wiktoria Bratborska   +2 more
exaly   +3 more sources

JAK inhibitors and black box warnings: what is the future for JAK inhibitors?

Expert Review of Clinical Immunology, 2023
Janus kinase inhibitors (JAKi) have dramatically improved the treatment of various autoimmune and myeloproliferative disorders. Recently, concern has arisen regarding their safety in patients with rheumatoid arthritis.Here, we provide a comprehensive summary of the major current and emerging JAKi and their indications, address recent studies on ...
Kate Tokareva, Pankti Reid, Victor Yang, David Liew, Alexander C. Peterson, Aaron Baraff, Jon Giles, Namrata Singh   +7 more
openaire   +3 more sources

JAK Inhibitors in the Treatment of Lichen Planopilaris

Skin Appendage Disorders, 2023
<b><i>Background:</i></b> Lichen planopilaris (LPP) is an autoimmune disorder leading to lymphocytic cicatricial alopecia. Different agents such as hydroxychloroquine, methotrexate, cyclosporine, and mycophenolate mofetil have been tried to control hair loss with limited efficacy. JAK inhibitors are immune-modulating drugs which
Maryam, Nasimi, Mahshid Sadat, Ansari
openaire   +3 more sources

JAK inhibitors and infections risk: focus on herpes zoster [PDF]

Therapeutic Advances in Musculoskeletal Disease, 2020
Currently, there is a growing interest in Janus kinase (JAK) intracellular signalling since targeted inhibitors against these pathways are proving effective in the treatment of a range of immune-mediated diseases, such as rheumatoid arthritis (RA ...
Iain B Mcinnes, Stefan Siebert
exaly   +2 more sources